The primary objective of this study was to evaluate the efficacy, safety and immunogenicity of the trastuzumab CT-P6 in combination with pertuzumab and chemotherapy as neoadjuvant treatment in patients with HER2-positive early breast cancer in RCP according to pCR in breast and axilla. The gene discussed is ERBB2; the disease is breast carcinoma.